相关实验视频

Updated: Jun 18, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

评估Nirsevimab在减少西班牙儿童RSV住院治疗的有效性

Sara Jimeno Ruiz^1,2,3,4, Adrián Peláez^5,6, Agustín Labourt^1,2,3,4

¹Departamento de Pediatría, Hospital HM Puerta del Sur, HM Hospitales, 28938 Madrid, Spain.

|October 26, 2024

概括

尼尔西维玛可显著减少呼吸道同胞病毒 (RSV) 在幼儿的住院治疗. 这种单克隆抗体为预防脆弱人群中严重RSV疾病提供了一个至关重要的新工具.

科学领域:

儿童传染病儿童传染病
免疫学免疫学免疫学
公共卫生公共卫生

背景情况:

呼吸道同胞病毒 (RSV) 是导致婴儿入院的主要原因.
尼尔塞维马布在预防严重RSV疾病方面表现有前途.
关于nirsevimab有效性的现实数据有限.

研究的目的:

评估Nirsevimab对RSV婴儿住院治疗的影响.
确定Nirsevimab在减少RSV疾病负担的有效性,在现实环境中.

主要方法:

对六个月以下婴儿RSV住院病例的回顾性研究.
在四个季节进行分析:COVID前,COVID后,COVID后,Nirsevimab前和Nirsevimab季节 (2023-2024年).

主要成果:

在6个月以下的婴儿中,nirsevimab显著减少了与RSV相关的住院治疗.
在3个月以下的婴儿中,住院病例减少了79.3%,在3-6个月的婴儿中减少了66.9%.
尼尔西维玛也减少了RSVLRTI病例的严重程度,降低了医疗保健负担.

结论:

尼尔西维马布在预防婴儿严重RSV感染和住院治疗方面发挥着至关重要的作用.
尼尔西维马布代表了儿科呼吸系统护理的重大进展.
这些发现支持Nirsevimab在脆弱的婴儿群体中使用.

关键词:

这就是为什么Nirsevimabab.与RSV相关的下呼吸道感染.减少医疗负担减少医疗负担儿科呼吸系统护理呼吸道同胞性病毒 (RSV)

更多相关视频

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

相关概念视频

Respiratory Syncytial Virus Disease

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...